Blood–Brain Barrier Disruption for the Treatment of Primary Brain Tumors: Advances in the Past Half-Decade

Purpose of Review To review relevant advances in the past half-decade in the treatment of primary brain tumors via modification of blood–brain barrier (BBB) permeability. Recent Findings BBB disruption is becoming increasingly common in the treatment of primary brain tumors. Use of mannitol in BBB d...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology reports 2024-03, Vol.26 (3), p.236-249
Main Authors: Virtanen, Piiamaria S., Ortiz, Kyle J., Patel, Ajay, Blocher, William A., Richardson, Angela M.
Format: Article
Language:English
Subjects:
Blood-brain barrier
Brain cancer
Brain tumors
Convection
Mannitol
Medicine
Medicine & Public Health
Membrane permeability
Oligonucleotides
Oncology
Review
Topical Collection on Neuro-oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of Review To review relevant advances in the past half-decade in the treatment of primary brain tumors via modification of blood–brain barrier (BBB) permeability. Recent Findings BBB disruption is becoming increasingly common in the treatment of primary brain tumors. Use of mannitol in BBB disruption for targeted delivery of chemotherapeutics via superselective intra-arterial cerebral infusion (SIACI) is the most utilized strategy to modify the BBB. Mannitol is used in conjunction with chemotherapeutics, oligonucleotides, and other active agents. Convection-enhanced delivery has become an attractive option for therapeutic delivery while bypassing the BBB. Other technologic innovations include laser interstitial thermal therapy (LITT) and focused ultrasound (FUS) which have emerged as prime modalities to directly target tumors and cause significant local BBB disruption. Summary In the past 5 years, interest has significantly increased in studying modalities to disrupt the BBB in primary brain tumors to enhance treatment responses and improve clinical outcomes.
ISSN:1523-3790
1534-6269
DOI:10.1007/s11912-024-01497-7